Last reviewed · How we verify

Sotagliflozin Low Dose — Competitive Intelligence Brief

Sotagliflozin Low Dose (Sotagliflozin Low Dose) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT1/SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT1/SGLT2 inhibitor SGLT1, SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Sotagliflozin Low Dose (Sotagliflozin Low Dose) — University of California, San Diego. Sotagliflozin inhibits both SGLT2 and SGLT1 transporters to reduce glucose reabsorption in the kidneys and intestines, lowering blood glucose levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sotagliflozin Low Dose TARGET Sotagliflozin Low Dose University of California, San Diego phase 3 SGLT1/SGLT2 inhibitor SGLT1, SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT1/SGLT2 inhibitor class)

  1. University of California, San Diego · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sotagliflozin Low Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/sotagliflozin-low-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: